SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Meta Expands AI Training With Employee Activity Tracking Tools 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
TEL AVIV, Israel, Feb. 25, 2016 -- Elbit Imaging Ltd. (“EI” or the “Company”) (TASE:EMITF) (NASDAQ:EMITF) announced today, further to the Company’s announcement dated February 1, 2016 regarding the Board of Directors resolution to approve new notes' Buy-Back plan of the Company's series H (“The Notes”) which are traded on the Tel Aviv Stock Exchange ("TASE"), the repurchases of the following Notes was executed since the 1st of February, 2016 to the date herein:
| Note | The acquiring corporation | Quantity purchased (Par value) | Weighted average price | Total amount paid(NIS) |
| Series H | Elbit Imaging Ltd. | 13,741,086 | 88.8 | 12,202,417 |
The entire repurchased notes since the 12th of October, 2015, as the first Notes buyback plan announcement, to the date herein:
| Note | The acquiring corporation | Quantity purchased (Par value) | Weighted average price | Total amount paid(NIS) |
| Series H | Elbit Imaging Ltd. | 69,731,629 | 89.15 | 62,170,416 |
About Elbit Imaging Ltd.
Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial centers - initiation, construction, and sale of commercial centers and other mixed-use property projects, predominantly in the retail sector, located in Central and Eastern Europe. In certain circumstances and depending on market conditions, the Group operates and manages commercial centers prior to their sale. (ii) Hotels - hotels operation and management. (iii) Medical industries and devices - (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment, and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. (iv) Plots in India - plots designated for sale initially designated to residential projects.
Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as “believe,” “expect,” “intend,” “estimate” and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, a change in market conditions, a decision to deploy the cash for other business opportunities and the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2014, under the caption “Risk Factors.” Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained in our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.
For Further Information: Company Contact Ron Hadassi Chairman of the Board of Directors Tel: +972-3-608-6048 Fax: +972-3-608-6050 [email protected]
